TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 1-year TLF (Target Lesion Failure)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in new HIV infections
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in AIDS deaths
Endpoint domain: Mortality/survival
Primary endpoint: Total WOMAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulatory time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary TGF-beta excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent variation of saliva P concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent variation of plasma P concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of single plasma P concentration with 24-hour mean plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chance of live birth
Endpoint domain: Mortality/survival
Primary endpoint: Risk of early pregnancy loss
Endpoint domain: Mortality/survival
Primary endpoint: posttraumatic stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma linoleic acid levels (18:2 omega‐6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Essential fatty acid deficiency ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sensitivity of arterial spin-labeling/SWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of arterial spin-labeling/SWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: agreement with DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma LPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum LDL-cholesterol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum HDL-cholesterol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fasting serum triacylglycerol values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency rates of at least 1 surviving twin
Endpoint domain: Mortality/survival
Primary endpoint: Dual survivors
Endpoint domain: Mortality/survival
Primary endpoint: Cure rate (Hb > 11 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treatment failure (hemoglobin < 10 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative requirement of packed red blood cells (PRBCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in dermatologic and urticaria-specific quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: need for additional analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal vasodilatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: fasting serum glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: left ventricular remodeling and dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time off work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Skin distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean increase in lower incisor inclination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral bleb area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral bleb vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-bleb-related peripheral conjunctiva vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma DA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma DA-S levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of elimination of DA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health knowledge test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dietary habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: estimated V(O2)max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Rate of successful RRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of intermediate adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pain control improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete response 0-48 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to IV iron supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fatal or nonfatal acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adequate intakes of discretionary foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate intakes of vegetables and fruits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dentinal hypersensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of the final restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of moderate to severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limitation of work due to neck pain
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Consultation with medical or health practitioners
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: anterior chamber aqueous contamination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: systolic and diastolic BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perioperative fluid administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial rhythm status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FMFA (Fetal Movement and Flexion Angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT (Nuchal Translucency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of happy facial expressions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sympathetic nerve activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of parotid glands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth from medial edge of gland to spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression of retinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of progression of retinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of extraocular cytomegalovirus infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mean peak concentration of sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak concentration of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance of sitagliptin and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Deaths averted
Endpoint domain: Mortality/survival
Primary endpoint: DALYs averted
Endpoint domain: Mortality/survival
Primary endpoint: Urological complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Graft survival at 1 and 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Successful ureteroscopy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HBV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maternal-fetal vertical transmission of HBV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking cessation rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of alcohol relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of drug relapse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean dose of lidocaine consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of neutropenia and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: total fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinician-reported Grade >2 neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient-reported tingling or numbness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ASAS20 standard rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total effective rate of Chinese medical syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsiveness to verbal command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment AHI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-treatment ESS scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: mean incremental QALYs
Endpoint domain: Resource use
Primary endpoint: Symptomatic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in handwashing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) increase at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bone turnover (NTx and BSAP) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of serum 25‐OH cholecalciferol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fecal levels of calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher health care costs associated with ASD
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Higher aggregate non-health care costs associated with ASD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Higher school costs associated with ASD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SIPSO physical integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHOQol-Bref psychological
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tendon elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in platelet-monocyte interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Access time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tc maintenance during cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous VC response to cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee OA symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood oxidative protein damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiorespiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean microleakage ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LSBMD z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary C-telopeptide excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total outflow facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Po/C ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: keloid recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of 1 point or more on EDSS from baseline lasting 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGE peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fullness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prospective consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean end-tidal isoflurane concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venogram-proven thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Insertion-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 3 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional and anesthiological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Viral load decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD4(+)CD25(high) regulatory T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD8(+)CD28(‐) effector cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rates for mumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of fever >38 degrees C
Endpoint domain: Adverse events/effects
Primary endpoint: Glycoprotein Ib expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet function (aggregation response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of false-positive screen results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: bipolar cautery use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: intraoperative margins needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inhibition of DPP IV activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief (area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal epithelial permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: prelens noninvasive tear breakup
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Canadian Occupational Performance Measure (performance subscale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PERMP total scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD‐RS‐IV total scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic and diastolic blood pressure reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cost per additional depression-free day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: onset time for sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak aortic and arterial enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelium-dependent flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of death and myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Incident LUTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain intensity VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: autonomous motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: extrinsic motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective episodes of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Reported glucose values < 60 mg/dL
Endpoint domain: Adverse events/effects
Primary endpoint: Live birth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micropush‐out bond strength of posts to dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion to radical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cancer progression rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gleason 7 or higher cancer rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total cumulative urine output after rehydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drink retention during the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall rate of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of small hyperplastic polyps (size < 5 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decreased physiological response (heart rate, blood lactate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compression velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast material volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum oestradiol (E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression of genes associated with muscle growth and remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonization on removal
Endpoint domain: Adverse events/effects
Primary endpoint: depression outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 2 esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: anxiety score difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual Platelet Aggregation (RPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes